Vbi Vaccines Stock Total Asset
VBI Vaccines fundamentals help investors to digest information that contributes to VBI Vaccines' financial success or failures. It also enables traders to predict the movement of VBI Stock. The fundamental analysis module provides a way to measure VBI Vaccines' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to VBI Vaccines stock.
VBI |
VBI Vaccines Company Total Asset Analysis
VBI Vaccines' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current VBI Vaccines Total Asset | 86.95 M |
Most of VBI Vaccines' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VBI Vaccines is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
CompetitionBased on the latest financial disclosure, VBI Vaccines has a Total Asset of 86.95 M. This is 98.84% lower than that of the Biotechnology sector and 95.6% lower than that of the Health Care industry. The total asset for all United States stocks is 99.7% higher than that of the company.
VBI Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VBI Vaccines' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of VBI Vaccines could also be used in its relative valuation, which is a method of valuing VBI Vaccines by comparing valuation metrics of similar companies.VBI Vaccines is currently under evaluation in total asset category among its peers.
VBI Fundamentals
Return On Equity | -4.2 | |||
Return On Asset | -0.29 | |||
Operating Margin | (9.68) % | |||
Current Valuation | 38.92 M | |||
Shares Outstanding | 28.68 M | |||
Shares Owned By Insiders | 6.76 % | |||
Shares Owned By Institutions | 13.00 % | |||
Number Of Shares Shorted | 276.87 K | |||
Price To Earning | (3.79) X | |||
Price To Book | 1.24 X | |||
Price To Sales | 0.20 X | |||
Revenue | 8.68 M | |||
Gross Profit | (10.19 M) | |||
EBITDA | (53.32 M) | |||
Net Income | (92.84 M) | |||
Cash And Equivalents | 82.41 M | |||
Cash Per Share | 0.32 X | |||
Total Debt | 53.04 M | |||
Debt To Equity | 0.32 % | |||
Current Ratio | 2.29 X | |||
Book Value Per Share | (0.22) X | |||
Cash Flow From Operations | (60.88 M) | |||
Short Ratio | 1.57 X | |||
Earnings Per Share | (3.54) X | |||
Target Price | 5.0 | |||
Number Of Employees | 131 | |||
Beta | 2.17 | |||
Market Capitalization | 1.87 M | |||
Total Asset | 86.95 M | |||
Retained Earnings | (582.45 M) | |||
Working Capital | (39.51 M) | |||
Current Asset | 7.89 M | |||
Current Liabilities | 3.03 M | |||
Net Asset | 86.95 M |
About VBI Vaccines Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze VBI Vaccines's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VBI Vaccines using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VBI Vaccines based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in VBI Stock
If you are still planning to invest in VBI Vaccines check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the VBI Vaccines' history and understand the potential risks before investing.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Stocks Directory Find actively traded stocks across global markets | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |